HEALTH
Scientists in Brazil are releasing genetically modified mosquitoes into the environment to combat soaring cases of dengue fever in the country. More than a million cases of the viral infection have been reported in the first two months of 2024, 226 per cent more than were reported in the same period in 2023. Various cities are in states of emergency. In February, Rio de Janeiro declared the outbreak a public health emergency after the city recorded more than 42,000 cases of the disease since the start of the year.
Almost half of the world’s population lives in areas with a risk of dengue infection. In Brazil the disease is endemic, meaning it is constantly circulating. Between 2003 and 2019, more than 11 million cases were reported in the country, with peak transmission normally occurring during the annual rainy season from October to May. Unusually large outbreaks occur roughly every three to four years. Only one in four people who are infected with the dengue virus develop symptoms of disease, which include fever, headaches and nausea. These symptoms generally clear within two to seven days. However, the disease can sometimes progress and become severe, leading to hospitalisation and possibly death.
There is no specific treatment available for the infection; instead, medical care aims to relieve patients’ pain and maintain their vitals. The disease can’t be spread directly from person to person. Faced with a rising number of dengue cases, health authorities in Brazil are testing alternative approaches to control the spread of the disease in addition to rolling out a vaccine. These strategies include the use of genetically modified mosquitoes, an effort spearheaded by biotech company Oxitec.
The company breeds male Aedes aegypti mosquitoes, the species that spreads the dengue fever virus to humans, that are genetically modified to carry a gene that kills any female offspring they spawn before the pests reach adulthood. Dengue fever is spread through the bites of female A. aegypti mosquitoes, so rele
